- Generic drugmakers gain key victory in ‘skinny label’ patent caseThe Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.BioPharma Dive · 1mo ago↗ source
- Innovent declares Phase 3 success for ADC that attracted huge Takeda dealInnovent Biologics' ADC candidate has passed a Phase 3 trial in advanced stomach cancer and is under priority review in China, but details of the success are still under wraps. The Phase 3 win will…Endpoints · 1mo ago↗ source
- Fulcrum lays off majority of staff; Seres extends runway into 2027👥 Fulcrum Therapeutics reduced to a shell: The biotech is letting go 48 of its 57 full-time employees, according to an SEC filing. The step comes after Fulcrum said